Payment overview · 2025
General Payments
$46.12
2 reported records · 2 companies
Healthcare provider profile · identity verified
Murray Jonas, MD
Allopathic & Osteopathic Physicians|General Practice · BROOKLYN, NY · NPI 1235131467
Verified facts
What the public records show
CMS Open Payments records show Murray Jonas, MD received $46.12 in general payments during 2025 across 2 reported records.
Merck Sharp & Dohme LLC accounted for 67.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexium by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $31.00 | 67.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.12 | 32.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $46.12 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $31.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.12 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 451 | 102 |
| Eliquis | Apixaban | 370 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 348 | 85 |
| Levothyroxine Sodium | Levothyroxine Sodium | 298 | 63 |
| Alprazolam | Alprazolam | 219 | 28 |
| Gabapentin | Gabapentin | 218 | 44 |
| Losartan Potassium | Losartan Potassium | 213 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 207 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 192 | 56 |
| Januvia | Sitagliptin Phosphate | 183 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 165 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 163 | 51 |
| Metformin Hcl | Metformin Hcl | 148 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 144 | 37 |
| Furosemide | Furosemide | 125 | 36 |
| Omeprazole | Omeprazole | 120 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 113 | 38 |
| Enalapril Maleate | Enalapril Maleate | 110 | 21 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 109 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 32 |
| Famotidine | Famotidine | 96 | 23 |
| Simvastatin | Simvastatin | 94 | 20 |
| Lorazepam | Lorazepam | 93 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 93 | 37 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 23 |
| Atenolol | Atenolol | 86 | 13 |
| Mupirocin | Mupirocin | 82 | 30 |
| Levetiracetam | Levetiracetam | 80 | 11 |
| Diazepam | Diazepam | 79 | 19 |
| Lisinopril | Lisinopril | 79 | 16 |
| Potassium Chloride | Potassium Chloride | 77 | 14 |
| Latanoprost | Latanoprost | 75 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 74 | suppressed |
| Nifedipine Er | Nifedipine | 74 | 16 |
| Clonazepam | Clonazepam | 69 | suppressed |
| Finasteride | Finasteride | 69 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 68 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 64 | 32 |
| Breo Ellipta | Fluticasone/Vilanterol | 63 | 14 |
| Glipizide | Glipizide | 61 | 13 |
| Hydrocortisone | Hydrocortisone | 60 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 60 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 58 | suppressed |
| Ezetimibe | Ezetimibe | 58 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 57 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 56 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 54 | suppressed |
| Torsemide | Torsemide | 53 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 14 |
| Memantine Hcl | Memantine Hcl | 52 | 12 |
| Montelukast Sodium | Montelukast Sodium | 51 | 12 |
| Mirtazapine | Mirtazapine | 50 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 49 | suppressed |
| Xarelto | Rivaroxaban | 48 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 47 | 15 |
| Lactulose | Lactulose | 45 | 12 |
| Phenobarbital | Phenobarbital | 45 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 43 | 12 |
| Ozempic | Semaglutide | 43 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 42 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 39 | suppressed |
| Lacosamide | Lacosamide | 39 | suppressed |
| Spironolactone | Spironolactone | 39 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 39 | 14 |
| Farxiga | Dapagliflozin Propanediol | 38 | suppressed |
| Meloxicam | Meloxicam | 38 | suppressed |
| Ketoconazole | Ketoconazole | 37 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 37 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 36 | 18 |
| Lidocaine | Lidocaine | 36 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 36 | 15 |
| Carvedilol | Carvedilol | 35 | suppressed |
| Insulin Lispro | Insulin Lispro | 35 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 33 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Jardiance | Empagliflozin | 31 | suppressed |
| Allopurinol | Allopurinol | 30 | suppressed |
| Cefdinir | Cefdinir | 30 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | suppressed |
| Brilinta | Ticagrelor | 28 | suppressed |
| Clotrimazole | Clotrimazole | 28 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 27 | suppressed |
| Naproxen | Naproxen | 27 | 15 |
| Lubiprostone | Lubiprostone | 26 | suppressed |
| Olanzapine | Olanzapine | 26 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 24 | 15 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 23 | suppressed |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 15 |
| Efavirenz-Emtric-Tenofov Disop | Efavirenz/Emtricit/Tenofovr Df | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 22 | suppressed |
| Prednisone | Prednisone | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Azithromycin | Azithromycin | 21 | 18 |
| Baclofen | Baclofen | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 21 | suppressed |
| Colchicine | Colchicine | 21 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Renvela | Sevelamer Carbonate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | 11 |
| Heparin Sodium | Heparin Sodium,porcine | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Efavirenz | Efavirenz | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Ritonavir | Ritonavir | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Complera | Emtricita/Rilpivirine/Tenof Df | 17 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 15 | suppressed |
| Ertapenem | Ertapenem Sodium | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 15 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | 12 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Aptivus | Tipranavir | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | 11 |
| Nexium | Esomeprazole Magnesium | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 12 | suppressed |
| Fluorometholone | Fluorometholone | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 12 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 12 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Simbrinza | Brinzolamide/Brimonidine Tart | 12 | suppressed |
| Cefadroxil | Cefadroxil | 11 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 11 | suppressed |
| Dexilant | Dexlansoprazole | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $46.12 · 2 records | Merck Sharp & Dohme LLC | AIRSUPRA, PIFELTRO | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error